Veracyte, Inc. (VCYT) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Is Veracyte, Inc. stock overvalued or undervalued in 2026?
As of October 5, 2026, Veracyte, Inc. (VCYT) trades at 32.7× earnings (P/E), against a median of 27.5× across the 157 pharma companies above $2bn in Kaplio's universe. Kaplio's verdict: fairly priced. At its sector median (27.5×) $38 (-16 %).
Kaplio overview: Veracyte, Inc.
Market cap $4B · 52 weeks $30 – $60 (21 % below the high) · P/E 32.7× · 2027 expected P/E 23.5× · Dividend none · Next earnings November 3, 2026 · expected EPS $0.43 · Price as of Oct 5 · accounts published Jul 30.
- Valuation: P/E 32.7× (fairly priced).
- Business: ROIC 7 % (weak).
- Balance sheet: Net debt/EBITDA −3.6× (solid).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (27.5×) $38 (-16 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 5 pass
- ROIC 6.7 %, fails.
- R&D / Revenue 13.7 %, borderline.
- Gross margin 69.6 %, borderline.
- FCF / Net Income 190.8 %, passes.
- Net debt / EBITDA −3.6×, passes.
Against its peers (reference peers) — Veracyte, Inc.: P/E 32.7×; EV/EBITDA 26.2×; ROIC 6.7 %; $3.7B. Amicus Therapeutics, Inc. (P/E —; EV/EBITDA 82.3×; ROIC -1.7 %; $4.5B), Apellis Pharmaceuticals, Inc. (P/E 38.7×; EV/EBITDA 45.5×; ROIC 6.0 %; $5.3B), Kiniksa Pharmaceuticals International, plc (P/E 70.8×; EV/EBITDA 50.4×; ROIC 9.7 %; $5.8B).
Profitability
| Return on Equity | 8.64% |
| Return on Invested Capital | 6.70% |
| Return on Assets | 7.70% |
| Gross Margin | 72.09% |
| Operating Margin | 17.03% |
| Net Margin | 20.37% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 9.16 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 21.11 |
Price Performance
| 1 month | +12.09% |
| 3 months | -15.06% |
| Year-to-date | +13.23% |
| 1 year | +32.27% |
| 3 years | +121.21% |
| 5 years | +8.61% |
Related companies: ADPT · IDYA · IRON · KNSA · LEGN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of VCYT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks